文献速递产科母胎医学

孕期接种COVID-19疫苗的理性策略

A reasoned approach towards administering COVID-19 vaccines to pregnant women.
PubMed 文献 · Prenat Diagn · 2021-06-30

超过50种SARS-CoV-2候选疫苗处于II/III期试验,多数疫苗试验将孕妇排除,仅两项未排除。孕期是重症COVID-19的危险因素,尤其合并症者,早产和母体发病率增加。本文讨论主要疫苗机制、效力、安全性及母婴获益,提出理性接种策略。

要点

  • 高暴露风险或合并症易致重症COVID-19的孕妇应优先接种。
  • 有不良反应危险因素者应相应咨询。
  • 通过共享决策和风险获益讨论支持患者自主权。

核心结论

  • 高暴露风险或合并症易致重症COVID-19的孕妇应优先接种疫苗。
  • 有不良反应危险因素者应接受相应咨询。
  • 通过共享决策和风险获益讨论支持孕妇自主权。

研究设计与样本

  • 本文为综述,讨论主要SARS-CoV-2疫苗的机制、效力、安全性及母婴获益。

主要发现

  • 超过50种SARS-CoV-2候选疫苗处于II/III期临床试验。
  • 多数疫苗试验将孕妇排除,仅两项未排除。
  • 孕期是重症COVID-19的危险因素,尤其合并症者,早产和母体发病率增加。

临床怎么用

  • 对高暴露风险或合并症易致重症COVID-19的孕妇优先接种。
  • 对有不良反应危险因素者进行相应咨询。
  • 通过共享决策和风险获益讨论支持孕妇自主权。

局限性

  • 除有限动物研究、逐渐出现的发育和生殖毒性数据及疫苗登记观察数据外,缺乏可靠信息指导孕妇安全接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are over 50 SARS-CoV-2 candidate vaccines undergoing Phase II and III clinical trials. Several vaccines have been approved by regulatory authorities and rolled out for use in different countries. Due to concerns of potential teratogenicity or adverse effect on maternal physiology, pregnancy has been a specific exclusion criterion for most vaccine trials with only two trials not excluding pregnant women. Thus, other than limited animal studies, gradually emerging development and reproductive toxicity data, and observational data from vaccine registries, there is a paucity of reliable information to guide recommendations for the safe vaccination of pregnant women. Pregnancy is a risk factor for severe COVID-19, especially in women with comorbidities, resulting in increased rates of preterm birth and maternal morbidity. We discuss the major SARS-CoV-2 vaccines, their mechanisms of action, efficacy, safety profile and possible benefits to the maternal-fetal dyad to create a rational approach towards maternal vaccination while anticipating and mitigating vaccine-related complications. Pregnant women with high exposure risks or co-morbidities predisposing to severe COVID-19 infection should be prioritised for vaccination. Those with risk factors for adverse effects should be counselled accordingly. It is essential to support patient autonomy by shared decision-making involving a risk-benefit discussion with the pregnant woman.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Pramanick A, Kanneganti A, Wong JLJ, et al. A reasoned approach towards administering COVID-19 vaccines to pregnant women. Prenat Diagn. 2021. PMID: 34191294. doi:10.1002/pd.5985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。